MedPath

A retrospective cohort study based on multi-center and propensity score matching was used to evaluate the effect of Tanreqing Injection on Influence of survival prognosis in patients with severe COVID-19 infectio

Phase 2
Conditions
severe COVID-19 infection
Registration Number
ITMCTR2024000103
Lead Sponsor
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) Conform to the criteria for moderate and severe diagnosis of the novel coronavirus infection Diagnosis and Treatment Protocol (Trial Version 9 and 10); Diagnostic criteria for patients with viral pneumonia in (Trial Version 9 and 10);
(2)Age range from 18 to 75 years old (including 18 and 75 years old), gender is not limited.

Exclusion Criteria

Exclude patients who experience the endpoint death event within 48 hours of hospital admission.

Study & Design

Study Type
Observational study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath